Illustratively, the phase 1b/2 BEGONIA trial (NCT03248492) exemplifies this approach by evaluating the synergistic effects of trastuzumab and durvalumab in patients with triple-negative breast cancer and low HER2 expression, demonstrating promising preliminary outcomes [33]. Here, ERBB2 is linked to triple-negative breast carcinoma.